



Contact: Frederick W. Driscoll
VP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000

**Novavax to Report Second Quarter 2010 Financial Results on
August 6, 2010**

Rockville, MD – July 30, 2010 – Novavax, Inc. (Nasdaq: NVAX) announced today that Dr. Rahul Singhvi, President & Chief Executive Officer, and members of senior management will provide a corporate update and review of second quarter 2010 financial results via a webcast and conference call on Friday, August 6, 2010, at 10:00 a.m. Eastern time.

To access the live audio webcast of the conference call, or the subsequent archived recording, visit the "Investors/Events" section of the company's website at www.novavax.com. Alternatively, callers may participate in the conference call by dialing 1-877-212-6076 (domestic) or 1-707-287-9331 (international). Webcast and telephone replays of the conference call will be available shortly after the completion of the call. To access the replay, callers should dial 1-800-642-1687 (domestic) or 1-706-645-9291 (international) and use passcode 89793634.

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

###